BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - NYSE Delayed price. Currency in USD

Biohaven Pharmaceutical Holding Company Ltd.

215 Church Street
New Haven, CT 06510
United States
203 404 0410

Full-time employees647

Key executives

NameTitlePayExercisedYear born
Dr. Vladimir CoricCEO & Director1.14MN/A1971
Mr. James EngelhartChief Financial Officer & Treasurer656.39kN/A1964
Ms. Kimberly GentileSr. VP of Clinical Operations614.09k1.31M1966
Dr. Elyse Stock M.D.Chief Medical Officer594.39k633.58k1958
Mr. William Jones M.B.A.Chief Commercial Officer of Migraine & Common Diseases1.3MN/A1964
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Corporate governance

Biohaven Pharmaceutical Holding Company Ltd.’s ISS governance QualityScore as of 8 December 2019 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.